Ixazomib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 669 publications
Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.
Journal: Cancers
Published: February 25, 2026
"Et tu, Brute?" -A Case of Ixazomib-Induced Cancer Therapy-Related Cardiac Dysfunction.
Journal: Internal medicine (Tokyo, Japan)
Published: February 23, 2026
Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection.
Journal: The Journal of general virology
Published: February 06, 2026
Structure-Based Design of Pan-Selective Peptide Epoxyketones for the Three Human Immunoproteasome Active Sites.
Journal: Journal of medicinal chemistry
Published: January 08, 2026
Clinical Analysis of Ixazomib-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Multiple Myeloma with 1q21 Amplification
Journal: Zhongguo shi yan xue ye xue za zhi
Published: January 08, 2026
Ixazomib-Lenalidomide-Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: A Hungarian Real-World Analysis.
Journal: Journal of clinical medicine
Published: December 01, 2025
Cardiovascular Adverse Events Associated With Carfilzomib, Bortezomib, and Ixazomib: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database With Anticancer Agents as the Reference Group.
Journal: In vivo (Athens, Greece)
Published: November 22, 2025
Solitary plasmacytoma of maxilla with Epstein Barr virus: A case report and literature review.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: October 29, 2025
Anthracyclines attenuate Nrf1-dependent proteolytic pathways and potentiate proteasome inhibitor cytotoxicity.
Journal: Molecular biology of the cell
Published: October 22, 2025
Recent Advancements in the Diversification and Applications of Boron-Containing Compounds in Medicinal Chemistry.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: October 19, 2025
Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system.
Journal: Frontiers in pharmacology
Published: September 24, 2025
Cardiovascular Safety of Carfilzomib in Patients with Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 10, 2025
Last Updated: 04/28/2026